Skip to Content

Carfilzomib

In the US, Carfilzomib (carfilzomib systemic) is a member of the drug class proteasome inhibitors and is used to treat Multiple Myeloma.

US matches:

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0868540-17-4

Chemical Formula

C40-H57-N5-O7

Molecular Weight

719

Therapeutic Categories

Antineoplastic agent

Proteasome inhibitor

Chemical Name

{(2S)-2-[(morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N¹-{(2S)-1-[(2R)-2-metyloxiran-2-yl]-4-metyl-1-oxopentan-2-yl}-L-phenylalaninamide (WHO)

Foreign Names

  • Carfilzomibum (Latin)
  • Carfilzomib (German)
  • Carfilzomib (French)
  • Carfilzomib (Spanish)

Generic Names

  • Carfilzomib (OS: USAN, JAN)
  • PR-171 (IS)
  • UNII-72X6E3J5AR (IS)

Brand Names

  • Kyprolis
    Amgen, Germany; Amgen, United Kingdom; Amgen Europa, Israel; Amgen Switzerland, Switzerland; Onyx Pharmaceuticals, United States

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide